Immucor Completes Acquisition of LIFECODES(R) Business from Hologic, Inc.

Immucor Completes Acquisition of LIFECODES(R) Business from Hologic, Inc.

NORCROSS, Ga., March 22, 2013 (GLOBE NEWSWIRE) -- Immucor, Inc., a global
leader in providing automated instrument-reagent systems to the blood
transfusion industry, has completed its acquisition of the LIFECODES business
from Hologic, Inc. (Nasdaq:HOLX).

"The addition of LIFECODES expands Immucor's specialty diagnostic footprint
with a highly complementary best-in-class product portfolio, including
transplant and other immune-monitoring products," said William A. Hawkins,
president and chief executive officer of Immucor. "At Immucor, our focus has
always been on helping blood banks, reference centers and hospitals find the
right match for patients in need of a blood transfusion. Our acquisition of
LIFECODES adds a worldwide leadership position in transplantation diagnostics
that is focused on helping reference centers and hospitals find the right
match for patients in need of organs and stem cells."

LIFECODES was previously a part of the San Diego-based Gen-Probe Incorporated
portfolio. Hologic acquired Gen-Probe in August 2012.

For more information about LIFECODES, visit

About Immucor

Founded in 1982, Immucor manufactures and sells a complete line of reagents
and systems used by hospitals, reference laboratories, and donor centers to
detect and identify certain properties of the cell and serum components of
blood prior to transfusion. Immucor markets a complete family of products for
all of its market segments, including two fully automated instruments for
serology testing – NEO® and Echo® – and its BioArray™ molecular BeadChip™
offering, which is CE marked in Europe and available on a research use only
basis in the U.S. Immucor is headquartered in Norcross, Georgia. For more
information, visit or call 1.855.IMMUCOR. 

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this communication contain forward-looking
statements within the meaning of Section27A of the Securities Act of 1933, as
amended, and Section21E of the Securities Exchange Act of 1934, as amended.
All statements, other than statements of historical facts, including, among
others, statements regarding the impact of the acquisition of the LIFECODES
business are forward-looking statements. Those statements include statements
regarding the intent, belief or current expectations of Immucor, Inc. (the
"Company") and members of its management team, as well as the assumptions on
which such statements are based, and generally are identified by the use of
words such as "may," "will," "seeks," "anticipates," "believes," "estimates,"
"expects," "plans," "intends," "should" or similar expressions.
Forward-looking statements are not guarantees of future events and involve
risks and uncertainties that actual events may differ materially from those
contemplated by such forward-looking statements. Many of these factors are
beyond the Company's ability to control or predict. Such factors include, but
are not limited to, unexpected costs or liabilities and those set forth in the
reports that the Company files from time to time with the SEC. These
forward-looking statements reflect the Company's expectations as of the date
hereof. The Company undertakes no obligation to update the information
provided herein.

CONTACT: Michele Howard, Vice President of Corporate
         Development and Communications
Press spacebar to pause and continue. Press esc to stop.